william millerIBRAHIM SALMAN SALAH ALKHATTABI2022-06-042022-05-302022-06-04111168https://drepo.sdl.edu.sa/handle/20.500.14154/66426Eptinezumab 100 mg and 300 mg treated with intravenous over a 30-minute period on day 0 and week 12 showed prolonged migraine prevention effects. Eptinezumab has a high safety profile, despite expressing some minor side effects. Eptinezumab would be a promising treatment if it was approved in Saudi Arabia.38enThesis